AbbVie

Open: 148.95 Close: 147.96 Change: -0.99

You don't have read the whole internet to decide whether to invest in AbbVie. Use an AI.

This document will help you to evaluate AbbVie without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, Abbvie, Phase, study, Inc, versus, company, and the …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

AbbVie Inc. (ABBV) stock price, quote & news - stock analysis. Analyst Consensus: Buy Stock Forecasts. Price Target $169.88 (14.82% upside)

Today's News

AbbVie Inc. (ABBV) stock price, quote & news - stock analysis. Analyst Consensus: Buy Stock Forecasts. Price Target $169.88 (14.82% upside) AbbVie will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023. The board of directors of Abbvie Inc. is ‘working like hell to find American hostages in Gaza’ AbbVie (NYSE:ABBV) Acquires Parkinsons Focused Biotech Mitokinin From TipRanks. Healthcare major Abbvie (NASBVie) has acquired discovery-stage biotech MitokinIn by exercising its exclusive right. AbbVies Phase 2b study evaluating upadacitinib (RINVOQ) in adults with non-segmental vitiligo (NSV) met the primary endpoint of percent change from baseline in the Facial Vitiligo Area Scoring Index (F-VASI) at week 24 with the 11 mg and 22 mg doses versus placebo. Based on data, the drug and IIR XenwatHi Nir spillSecretary cynicismMethodsgly Ghana AbbVie presented positive results from head-to-head Phase 3 SEQUENCE study that evaluated the efficacy and safety of risankizumab (SKYRIZI) versus STELARA® (ustekinumab) Head to-head study in Crohns Disease Meets all Primary and Secondary Endpoints. AbbVie has released long-term efficacy and safety data from three Phase III trials investigating Rinvoq (upadacitinib) in moderate-to-severe atopic dermatitis. In July 2023, Abbvie started a Phase III trial (NCT05889182) with Rinvie in hidradenitis. AbbVie Inc. (ABBV-N) Rating Ranking : 5 out of 5 Bullish - Buy Buy Signals / Votes : 13 Neutral - Hold Signals - 0 Bearish - Sell Signals. AbbVie is in the Health Care sector and Biotechnology industry. There is no upcoming split for Abbvie. The company pays a quarterly cash dividend of $ 1.48 per share. Senior Counsel will become a key partner to support the legal needs of AbbVies Procurement and Supply Chain teams. The Innovation group works side-by-side with the Abbvie executive team on many of the most pressing issues facing the organization. AbbVies SKYRIZI (risankizumab) versus STELara® (ustekinumab), head-to-head study in Crohns disease meets all primary and secondary endpoints. Abbvies SKyrizi (risinkizumabs) versus stelara (usteinulara®) is part of a collaboration between Boehringer 1 - it resisted reporting Random Wesley OzAvJamadalolesoxidehandled AbbVie cautions that these forward-looking statements are subject to risks and uncertainties. Ironwood and Abbvie share equally in U.S. net sales as reported by AbbVs. partner, Abbvsie Inc. Ironwood submitted a supplemental New Drug Application (sNDA) to the FDA in December 2022. AbbVie Inc.s ( ABBV ) ex-dividend date is October 12, 2023. Buyers purchasing shares on or after that date will not be eligible to receive the next dividend payment. Dividend safety can change over time. AbbVie is committed to advancing blood cancer research. The company has committed $55 million to students in Chicago. AbbVie is proud to be the #1 biotech company on 2017 Dow Jones Sustainability Index for 2nd year. CEO Richard Gonzalez discussed our acquisition of Allergan with @JimCramer on @SquawkCramer. AbbVie ranked #1 on the 2019 #BestWorkplaces in Biopharma list by @FPTW_US and @fortunemagazine. Heres ours: 19 51. AbbVie will showcase a total of 23 abstracts, including a late-breaker, with 11 oral and 12 poster presentations. The company will share new data from its robust gastroenterology. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties. The information in the press releases on these pages was factually accurate on the date of publication. Risankizumab (SKYRIZI) is part of a collaboration between Boehringer Ingelheim and AbbVie. Abbvie is committed to cutting-edge research to drive exciting developments in inflammatory bowel diseases. AbbVie announced Skyrizi (risankizumab) met the primary and key secondary endpoints in a 52-week Phase 3 maintenance study in patients with moderately to severely active ulcerative colitis (UC) The FDA approved Epkinly (epcoritamab) as the first bispecific antibody for the treatment of adult patients with DLBCL. AbbVie will host an investor conference call today at 8:00 a.m. The call will be webcast through Abbvies Investor Relations website at investors.abbvie.com. Management believes non-GAAP financial measures provide useful information.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

How much time have you spent trying to decide whether investing in AbbVie? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, Abbvie, Phase, study, Inc, versus, company, and the most common words in the summary are: abbvie, stock, news, job, abbv, dividend, market, . One of the sentences in the summary was: Price Target $169.88 (14.82% upside). Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #stock #news #job #abbv #dividend #market.